Abivax
Paris
About Abivax
Abivax is a clinical-stage biotechnology company, that mobilizes the body’s natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Their aim is to use Abivax's drug development platforms to provide novel and effective treatments to patients with large unmet needs in these therapeutic areas.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $1.2B
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2025)
- Ticker: nasdaq:ABVX
- Website: abivax.com
- Phone: +33 (0) 1 53 83 09 63
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/abivax-101868 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.